FindTrial
Sign In

Liver protective drug action of homoeopathic preparation of Myrica cerifera 3C on Non alcoholic fatty liver disease

Preclinical studies on Molecular understanding of Hepatoprotective drug action of homoeopathic preparation of Myrica cerifera 3C and its clinical effectiveness in comparison to Individualised homoeopathic medicine in patients suffering from the Non Alcoholic Fatty Liver Disease with respect to Liver Function Test parameters: An open label Randomised Controlled Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/02/040009
Enrollment
120
Registered
2022-02-03
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: Myrica cerifera 3C and individualised Homoeopathic medicine: Two-four globules of Myrica cerifera 3C once in a day for two months and one dose in alternative days for next two months. I

Sponsors

Dr Raja Manoharan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Conformed Diagnosis of NAFLD established by ultrasound. There is no significant alcohol consumption There are no competing aetiologies for hepatic steatosis There are no co existing causes for chronic liver disease Alanine transaminase (ALT) more than 40 UL as considered elevated. Providing written informed consent to participate.

Exclusion criteria

Exclusion criteria: Absence of regular or excessive use of alcohol (more than 20 gram per day in men and 10 gram in female). History of bowel surgery, Bariatric surgery or undergoing evaluation for bariatric surgery for obesity, extensive small bowel resection or orthotopic liver transplants. History of other chronic liver disease (Viral hepatitis B or C, autoimmune hepatitis, Cholestatic and metabolic liver diseases) and hemochromatosis. Known case of cirrhosis Patients with Hypothyroidism History of myopathies or evidence of active muscle disease. History of bladder disease and /or haematuria or has haematuria except due to UTI. Pregnant women, Lactating women & paediatric age group ( Uncontrolled Diabetes, Hypertension, Mental illness or depression, kidney or heart disease, Malignant conditions as well as with history of stroke. Person under corticosteroid therapy. Patients who are too sick for consultation and not willing to cooperate Unwilling to take part and not giving consent to join the study

Design outcomes

Primary

MeasureTime frame
Total bilirubin ALT AST Prothrombin time Albumin Globulin ratioTimepoint: All the parameters will be assessed at baseline after 2 months and after 4 months—

Secondary

MeasureTime frame
USG (Whole abdomen) alkaline phosphatase.Timepoint: alkaline phosphatase will be assessed baseline after 2 months and after 4 months and USG (Whole abdomen) will be assessed baseline and after 4 months—

Countries

India

Contacts

Public ContactDrRaja Manoharan

S N Bose National Centre for Basic Sciences (SNBNCBS)

skpal.snbncbs@gmail.com9331295025

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026